Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan

K. Nouso; K. Miyahara; D. Uchida; Kenji Kuwaki; N. Izumi; M. Omata; T. Ichida; M. Kudo; Y. Ku; N. Kokudo; M. Sakamoto; O. Nakashima; T. Takayama; O. Matsui; Y. Matsuyama; K. Yamamoto

doi:10.1038/bjc.2013.542

Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan

K. Nouso, K. Miyahara, D. Uchida, Kenji Kuwaki, N. Izumi, M. Omata, T. Ichida, M. Kudo, Y. Ku, N. Kokudo, M. Sakamoto, O. Nakashima, T. Takayama, O. Matsui, Y. Matsuyama, K. Yamamoto

University Hospital

Research output: Contribution to journal › Article › peer-review

98 Citations (Scopus)

Abstract

Background:The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.Methods:The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.Results:A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).Conclusion:For advanced HCC, HAIC is considered to be an effective treatment.

Original language	English
Pages (from-to)	1904-1907
Number of pages	4
Journal	British Journal of Cancer
Volume	109
Issue number	7
DOIs	https://doi.org/10.1038/bjc.2013.542
Publication status	Published - Oct 1 2013

Keywords

5-fluorouracil
chemotherapy
cisplatin
hepatocellular carcinoma
liver neoplasm
propensity score

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2013.542

Cite this

Nouso, K., Miyahara, K., Uchida, D., Kuwaki, K., Izumi, N., Omata, M., Ichida, T., Kudo, M., Ku, Y., Kokudo, N., Sakamoto, M., Nakashima, O., Takayama, T., Matsui, O., Matsuyama, Y., & Yamamoto, K. (2013). Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan. British Journal of Cancer, 109(7), 1904-1907. https://doi.org/10.1038/bjc.2013.542

Nouso, K, Miyahara, K, Uchida, D, Kuwaki, K, Izumi, N, Omata, M, Ichida, T, Kudo, M, Ku, Y, Kokudo, N, Sakamoto, M, Nakashima, O, Takayama, T, Matsui, O, Matsuyama, Y & Yamamoto, K 2013, 'Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan', British Journal of Cancer, vol. 109, no. 7, pp. 1904-1907. https://doi.org/10.1038/bjc.2013.542

@article{00fc98011cbf47dfa4068bfce13fe40e,

title = "Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan",

abstract = "Background:The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.Methods:The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.Results:A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).Conclusion:For advanced HCC, HAIC is considered to be an effective treatment.",

keywords = "5-fluorouracil, chemotherapy, cisplatin, hepatocellular carcinoma, liver neoplasm, propensity score",

author = "K. Nouso and K. Miyahara and D. Uchida and Kenji Kuwaki and N. Izumi and M. Omata and T. Ichida and M. Kudo and Y. Ku and N. Kokudo and M. Sakamoto and O. Nakashima and T. Takayama and O. Matsui and Y. Matsuyama and K. Yamamoto",

note = "Funding Information: This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.",

year = "2013",

month = oct,

day = "1",

doi = "10.1038/bjc.2013.542",

language = "English",

volume = "109",

pages = "1904--1907",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan

AU - Nouso, K.

AU - Miyahara, K.

AU - Uchida, D.

AU - Kuwaki, Kenji

AU - Izumi, N.

AU - Omata, M.

AU - Ichida, T.

AU - Kudo, M.

AU - Ku, Y.

AU - Kokudo, N.

AU - Sakamoto, M.

AU - Nakashima, O.

AU - Takayama, T.

AU - Matsui, O.

AU - Matsuyama, Y.

AU - Yamamoto, K.

N1 - Funding Information: This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background:The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.Methods:The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.Results:A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).Conclusion:For advanced HCC, HAIC is considered to be an effective treatment.

AB - Background:The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.Methods:The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.Results:A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).Conclusion:For advanced HCC, HAIC is considered to be an effective treatment.

KW - 5-fluorouracil

KW - chemotherapy

KW - cisplatin

KW - hepatocellular carcinoma

KW - liver neoplasm

KW - propensity score

UR - http://www.scopus.com/inward/record.url?scp=84885176975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885176975&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.542

DO - 10.1038/bjc.2013.542

M3 - Article

C2 - 24008659

AN - SCOPUS:84885176975

SN - 0007-0920

VL - 109

SP - 1904

EP - 1907

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this